Logo image of EAR

EARGO INC (EAR) Stock Fundamental Analysis

NASDAQ:EAR - Nasdaq - US2700872086 - Common Stock - Currency: USD

2.57  -0.11 (-4.1%)

After market: 2.6 +0.03 (+1.17%)

Fundamental Rating

3

Overall EAR gets a fundamental rating of 3 out of 10. We evaluated EAR against 187 industry peers in the Health Care Equipment & Supplies industry. While EAR seems to be doing ok healthwise, there are quite some concerns on its profitability. EAR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EAR has reported negative net income.
EAR had a negative operating cash flow in the past year.
EAR had negative earnings in each of the past 5 years.
In the past 5 years EAR always reported negative operating cash flow.
EAR Yearly Net Income VS EBIT VS OCF VS FCFEAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -154.97%, EAR is doing worse than 89.90% of the companies in the same industry.
Looking at the Return On Equity, with a value of -239.84%, EAR is doing worse than 82.83% of the companies in the same industry.
Industry RankSector Rank
ROA -154.97%
ROE -239.84%
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-90.17%
ROE(3y)-133.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EAR Yearly ROA, ROE, ROICEAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 1K 2K 3K 4K

1.3 Margins

The Gross Margin of EAR (41.94%) is worse than 63.13% of its industry peers.
EAR's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.62%
GM growth 5Y3.34%
EAR Yearly Profit, Operating, Gross MarginsEAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

EAR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EAR has been increased compared to 1 year ago.
EAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EAR Yearly Shares OutstandingEAR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
EAR Yearly Total Debt VS Total AssetsEAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

EAR has an Altman-Z score of -13.28. This is a bad value and indicates that EAR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.28, EAR is doing worse than 82.83% of the companies in the same industry.
EAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.28
ROIC/WACCN/A
WACC9.84%
EAR Yearly LT Debt VS Equity VS FCFEAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 100M -100M

2.3 Liquidity

EAR has a Current Ratio of 3.22. This indicates that EAR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.22, EAR is in line with its industry, outperforming 46.97% of the companies in the same industry.
A Quick Ratio of 2.97 indicates that EAR has no problem at all paying its short term obligations.
EAR has a Quick ratio (2.97) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 2.97
EAR Yearly Current Assets VS Current LiabilitesEAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.73% over the past year.
EAR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.51%.
The Revenue has been growing by 41.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.77%
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y41.27%
Sales Q2Q%4.55%

3.2 Future

The Earnings Per Share is expected to grow by 1.04% on average over the next years.
Based on estimates for the next years, EAR will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.
EPS Next Y93.38%
EPS Next 2Y1.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.87%
Revenue Next 2Y6.88%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EAR Yearly Revenue VS EstimatesEAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EAR Yearly EPS VS EstimatesEAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EAR. In the last year negative earnings were reported.
Also next year EAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EAR Price Earnings VS Forward Price EarningsEAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EAR Per share dataEAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.04%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EARGO INC

NASDAQ:EAR (2/15/2024, 8:00:01 PM)

After market: 2.6 +0.03 (+1.17%)

2.57

-0.11 (-4.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-22 2024-02-22/amc
Earnings (Next)05-09 2024-05-09/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners40.87%
Ins Owner Change0%
Market Cap53.38M
Analysts45
Price Target2.04 (-20.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.17%
Min Revenue beat(2)-3.73%
Max Revenue beat(2)-2.61%
Revenue beat(4)2
Avg Revenue beat(4)26.56%
Min Revenue beat(4)-3.73%
Max Revenue beat(4)58.7%
Revenue beat(8)3
Avg Revenue beat(8)-8.72%
Revenue beat(12)6
Avg Revenue beat(12)-7.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-57.98
EYN/A
EPS(NY)-56.76
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.63
OCFYN/A
SpS1.98
BVpS2.18
TBVpS2.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -154.97%
ROE -239.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.94%
FCFM N/A
ROA(3y)-76.89%
ROA(5y)-90.17%
ROE(3y)-133.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.62%
GM growth 5Y3.34%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.18%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 2.97
Altman-Z -13.28
F-Score5
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)123.26%
Cap/Depr(5y)197.27%
Cap/Sales(3y)7.58%
Cap/Sales(5y)9.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.77%
EPS Next Y93.38%
EPS Next 2Y1.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y41.27%
Sales Q2Q%4.55%
Revenue Next Year19.87%
Revenue Next 2Y6.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.69%
OCF growth 3YN/A
OCF growth 5YN/A